REG - Integrated Diag Hdgs - Notice of Results

Integrated Diagnostics HoldingsAnnouncement

01/06/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA6479Na&default-theme=true

RNS Number : 6479N  Integrated Diagnostics Holdings PLC  01 June 2022

Integrated Diagnostics Holdings Plc Notice of Results

 

1 June 2022

 

(London) Integrated Diagnostics Holdings ("IDH," "the Group," or "the
Company"), a leading consumer healthcare company with operations in Egypt,
Jordan, Sudan and Nigeria, will publish its results for the quarter ended 31
March 2022 on Wednesday, 8 June 2022 at 7am (UK).

 

An analyst and investor call will be hosted at 14pm (UK) | 15pm (Egypt) on
Wednesday, 8 June 2022. You can access the call by clicking on this link
(https://efghermesevents.webex.com/mw3300/mywebex/default.do?nomenu=true&siteurl=efghermesevents&service=6&rnd=0.8311726298096395&main_url=https%3A%2F%2Fefghermesevents.webex.com%2Fec3300%2Feventcenter%2Fevent%2FeventAction.do%3FtheAction%3Ddetail%26%26%26EMK%3D4832534b00000005f3a1ec673218184f2342551b78f0455b76d4e322cdbd659eff0cc8c2dca46a14%26siteurl%3Defghermesevents%26confViewID%3D228880326171036429%26encryptTicket%3DSDJTSwAAAAXqpAKNxKlVjlm74x4NtDgQscJH0APGJ4r3RvHiIjClSA2%26)
, and you may dial in using the conference call details below:

 

• Event number: 2372 285 1168

• Event password: 7qdVVHnZT46

 

For more information about the event, please contact: halaa@EFG-HERMES.com
(mailto:halaa@EFG-HERMES.com)

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa
with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands
include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab
(Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab
(Nigeria). A long track record for quality and safety has earned IDH a trusted
reputation, as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 502 branches as at
year-end 2021, IDH will continue to add laboratories through a Hub, Spoke and
Spike business model that provides a scalable platform for efficient
expansion. Beyond organic growth, the Group's expansion plans include
acquisitions in new Middle Eastern, African, and Asian markets where its model
is well-suited to capitalise on similar healthcare and consumer trends and
capture a significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market of the
London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing
on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com
(http://idhcorp.com) .

 

The person responsible for arranging the release of this announcement is Nancy
Fahmy, Investor Relations Director at IDH.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com
(mailto:nancy.fahmy@idhcorp.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFZGGVVMNGZZM